High-intensity focused ultrasound (HIFU) developer USHIFU announced that its Sonablate 500 medical device is now available for the first time for prostate cancer patients living in Brazil, at the Hospital Nossa Senhora das Graças in Curitiba.
In addition, the Center Zdorovie in Rostov-on-Don, Russia, is now offering Sonablate HIFU treatments to prostate cancer patients. This is the second installation in Russia, the company said.
Sonablate HIFU is a targeted approach to treating prostate cancer with precision-focused ultrasound energy. The product is currently under U.S. Food and Drug Administration (FDA) investigation in the U.S., but it is commercially available in more than 30 countries.
The company claims that more than 9,000 patients have undergone Sonablate HIFU outside the U.S.
